Skip to main content
Clinical Trials/NCT03530306
NCT03530306
Completed
Not Applicable

Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2 (TENT-A2)

Neuromod Devices Ltd.1 site in 1 country191 target enrollmentMarch 20, 2018
ConditionsTinnitus

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Tinnitus
Sponsor
Neuromod Devices Ltd.
Enrollment
191
Locations
1
Primary Endpoint
Tinnitus Handicap Inventory (THI)
Status
Completed
Last Updated
last year

Overview

Brief Summary

This is a four arm, patient subtyping and parameter optimisation study for a neuromodulation treatment for tinnitus.

Detailed Description

Participants with chronic tinnitus will be provided with a CE marked neuromodulation device. Participants are randomized to one of four different treatment arms. The treatment period is intended for 12 weeks of use. Based on the clinical investigation plan, participants are informed that their stimulation settings can change between the first and second halves of the treatment period and that the differences may be perceptually noticeable. Differences in tinnitus severity scores will be compared between and within treatment arms.

Registry
clinicaltrials.gov
Start Date
March 20, 2018
End Date
July 18, 2019
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Neuromod Devices Ltd.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 18 to 70 years of age
  • Ability to read and understand English
  • Willing and able to provide informed consent
  • Willing to commit to the full duration of the study
  • Baseline Tinnitus Handicap Inventory (THI) score of \>= 38 points
  • Subjective tinnitus of 3 months to 10 years
  • Maximum AC pure-tone audiometry hearing loss of 80 dB HL in any test frequency in the set {2,3,4,6,8}kHz or 40 dB HL in the set {250,500,1000}Hz either unilaterally or bilaterally
  • Baseline Minimum Masking Level (MML) of 20 to 80 dB HL
  • Tonal tinnitus

Exclusion Criteria

  • Diagnosed with objective tinnitus
  • Commenced usage of hearing aid within the last 90 days
  • Cases where pulsatility is the dominant feature of tinnitus
  • Patients whose tinnitus cannot be masked during Minimum Masking Level (MML) assessment
  • Meniere's disease
  • Significantly severe Loudness Discomfort Level (LDL, less than 30 dB SL)
  • Depression or neuro-psychological condition, previously diagnosed or identified from the State-Trait Anxiety Inventory (STAI) with score greater than 120
  • Diagnosed with somatic tinnitus resulting from head or neck injury
  • Temporomandibular Joint Disorder (TMJ)
  • Current or previous involvement in medico-legal cases

Outcomes

Primary Outcomes

Tinnitus Handicap Inventory (THI)

Time Frame: Between-arm and within-arm changes in THI after 6 weeks of treatment

Study Sites (1)

Loading locations...

Similar Trials